CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for hematologists, medical oncologists, hematology-oncology fellows, and other healthcare providers involved in the treatment of acute myeloid leukemia and myelodysplastic syndromes.
  
  LEARNING OBJECTIVES

  • Evaluate the importance of age, performance status and other biological and disease-related factors in the selection and sequencing of therapy for patients with various presentations of acute myeloid leukemia (AML).
  • Appreciate published clinical research findings with venetoclax in combination with azacitidine, decitabine or low-dose cytarabine for patients with newly diagnosed AML not eligible for intensive therapy, and identify individuals appropriate for treatment with this novel agent.
  • Reflect on available research with approved FLT3 inhibitors, and use this information to guide clinical care for patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
  • Develop an understanding of published data with and the current role of IDH1/2 inhibitors for patients with newly diagnosed or relapsed/refractory AML and an IDH1 or IDH2 mutation, and incorporate these agents into current management algorithms.
  • Recall published research data with promising investigational agents and strategies under evaluation for AML, and counsel appropriately selected patients regarding clinical trial enrollment.
  • Recognize the importance of age, performance status, cytogenetic profile and other patient- and disease-related factors in the selection and sequencing of therapy for lower- and higher-risk myelodysplastic syndromes (MDS).
  • Recollect mechanisms of action of, available data with and ongoing studies evaluating novel agents and approaches for lower- and higher-risk MDS, and counsel appropriately selected patients about the potential benefits of clinical trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation components and a short post-test, enables the participant to earn up to 1.75 (audio) and 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/MTPAMLMDS23/Part3/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/MTPAMLMDS23/Part3/Video.
  
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/MTPAMLMDS23/Part3/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/MTPAMLMDS23/Part3.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Richard M Stone, MD
  Lunder Family Chair in Leukemia
  Chief of Staff
  Dana-Farber Cancer Institute
  Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: AbbVie Inc, Amgen Inc, AvenCell, BerGenBio ASA, Bristol Myers Squibb, Celularity, CTI Biopharma, a Sobi company, Curis Inc, Daiichi Sankyo Inc, GSK, Hemavant, Jazz Pharmaceuticals Inc, Kura Oncology, Lava Therapeutics, Ligand Pharmaceuticals, Redona Therapeutics, Rigel Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Aptevo Therapeutics, Epizyme Inc, Syntrix Pharmaceuticals, Takeda Pharmaceuticals USA Inc.
  
  SURVEY PARTICIPANTS — Andrew M Brunner, MD — Advisory Committee: Agios Pharmaceuticals Inc, Acceleron Pharma, Bristol Myers Squibb, Gilead Sciences Inc, Keros Therapeutics, Lava Therapeutics, Novartis, Rigel Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc. Naval Daver, MD — Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Arog Pharmaceuticals Inc, Astellas, Bristol Myers Squibb, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, ImmunoGen Inc, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Menarini Group, Novartis, Pfizer Inc, Servier Pharmaceuticals LLC, Shattuck Labs, Stemline Therapeutics Inc, Syndax Pharmaceuticals Inc, Trillium Therapeutics Inc; Contracted Research: AbbVie Inc, Amgen Inc, Astellas, Bristol Myers Squibb, Daiichi Sankyo Inc, Fate Therapeutics, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlycoMimetics Inc, Hanmi Pharmaceutical, ImmunoGen Inc, Kite, A Gilead Company, NovImmune SA, Pfizer Inc, Servier Pharmaceuticals LLC, Trillium Therapeutics Inc, Trovagene. Courtney D DiNardo, MD, MSCE — Advisory Committee: AbbVie Inc, Astellas, Bristol Myers Squibb, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Jazz Pharmaceuticals Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Rigel Pharmaceuticals Inc, Schrödinger, Servier Pharmaceuticals LLC; Contracted Research: AbbVie Inc, Astex Pharmaceuticals, Bristol Myers Squibb, Foghorn Therapeutics, Immune-Onc Therapeutics Inc, Servier Pharmaceuticals LLC; Data and Safety Monitoring Board/Committee: Genmab US Inc. Amir Fathi, MD — Consulting Agreements: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Autolus, Bristol Myers Squibb, Celgene Corporation, Daiichi Sankyo Inc, EnClear Therapies, Forma Therapeutics, Genentech, a member of the Roche Group, Gilead Sciences Inc, ImmunoGen Inc, Ipsen Biopharmaceuticals Inc, Mablytics, Menarini Group, Novartis, Orum Therapeutics, Pfizer Inc, PureTech Health, Remix Therapeutics, Rigel Pharmaceuticals Inc, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc; Contracted Research (to Institution): AbbVie Inc, Bristol Myers Squibb, Servier Pharmaceuticals LLC; Data and Safety Monitoring Board/Committee: Takeda Pharmaceuticals USA Inc. Daniel A Pollyea, MD, MS — Advisory Committee: Daniel A Pollyea, MD, MS — Advisory Committee: AbbVie Inc, Adicet Bio, Arcellx, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, BerGenBio ASA, Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, HiberCell, ImmunoGen Inc, Jazz Pharmaceuticals Inc, Kura Oncology, Link Pharma, Magenta Therapeutics, Medivir AB, Novartis, OncoVerity, Qihan Biotech, Rigel Pharmaceuticals Inc, Ryvu Therapeutics, Seres Therapeutics, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc, Zentalis Pharmaceuticals; Consulting Agreements: AbbVie Inc, Aptevo Therapeutics, Schrödinger, Syros Pharmaceuticals Inc; Contracted Research: AbbVie Inc, Bristol Myers Squibb, Karyopharm Therapeutics, Teva Oncology; Data and Safety Monitoring Board/Committee: Aptevo Therapeutics, GlycoMimetics Inc. Gail J Roboz, MD — Consulting Agreements: AbbVie Inc, Amgen Inc, argenx, AstraZeneca Pharmaceuticals LP, bluebird bio, Blueprint Medicines, Bristol Myers Squibb, Caribou Biosciences Inc, Celgene Corporation, Daiichi Sankyo Inc, Ellipses Pharma, GSK, Janssen Biotech Inc, Jasper Therapeutics Inc, Jazz Pharmaceuticals Inc, Molecular Partners, Novartis, Pfizer Inc, Rigel Pharmaceuticals Inc, Roche Laboratories Inc, Syndax Pharmaceuticals Inc, Telix Pharmaceuticals Limited; Data and Safety Monitoring Board/Committee: Takeda Pharmaceuticals USA Inc. Eunice S Wang, MD — Advisory Committee and Consulting Agreements: AbbVie Inc, Bristol Myers Squibb, CTI Biopharma Corp, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, GSK, Johnson & Johnson Pharmaceuticals, Kite, A Gilead Company, Kura Oncology, Novartis, Rigel Pharmaceuticals Inc, SELLAS Life Sciences, Sumitomo Dainippon Pharma Oncology Inc; Data and Safety Monitoring Board/Committee: AbbVie Inc, Gilead Sciences Inc; Speakers Bureau: Astellas, Kura Oncology, Pfizer Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from Daiichi Sankyo Inc, Gilead Sciences Inc, and Taiho Oncology Inc.
  
  Release date: January 2024
  Expiration date: January 2025
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.